TY - JOUR T1 - Five-year Outcomes of Chemotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Oesophagectomy in Oesophageal Cancer JF - Anticancer Research JO - Anticancer Res SP - 5829 LP - 5835 DO - 10.21873/anticanres.14601 VL - 40 IS - 10 AU - YUICHIRO TANISHIMA AU - KATSUNORI NISHIKAWA AU - YASUHIRO ARAKAWA AU - AKIRA MATSUMOTO AU - MASAMI YUDA AU - YUJIRO TANAKA AU - NORIO MITSUMORI AU - KATSUHIKO YANAGA Y1 - 2020/10/01 UR - http://ar.iiarjournals.org/content/40/10/5829.abstract N2 - Background: Preoperative chemotherapy with surgery is the most effective treatment modality in Japan for advanced oesophageal squamous cell carcinoma (OSCC). We evaluated the long-term outcomes associated with preoperative docetaxel/cisplatin/5-fluorouracil (DCF) administration followed by oesophagectomy in OSCC. Patients and Methods: Overall, 76 consecutive patients with cStage IB-IIIC OSCC were enrolled. After two cycles of preoperative DCF, oesophagectomy was performed. Survival monitoring was performed and relevant risk factors were analysed. Results: The median follow-up period was 88.3 months. The 5-year overall and recurrence-free survival rates were 51% and 43%, respectively. In the multivariable analysis, cT3 stage [hazard ratio (HR)=1.81, 95% confidence interval (CI)=1.08-6.16], incomplete chemotherapy (HR=2.35, 95% CI=1.37-4.02), poor clinical response (HR=1.82, 95% CI=1.01-3.29), and postoperative complications (HR=2.11, 95% CI=1.14-3.90) were independent predictors of poorer overall survival. Conclusion: The 5-year outcomes of preoperative DCF with oesophagectomy were favourable. Our findings can aid in the formulation of strategies aimed at improving prognosis in OSCC. ER -